Eastwood Bio-Medical Canada (TSXV:EBM) ROCE %: 0.00% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:EBM Eastwood Bio-Medical Canada Inc TSXV:EBM
25 GF Score
Price C$0.99
GF Value C$0.53
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Eastwood Bio-Medical Canada ROCE %?

Eastwood Bio-Medical Canada TSXV:EBM +1.02% 25 ROCE % is 0.00% as of Apr. 2026. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eastwood Bio-Medical Canada's annualized ROCE % for the quarter that ended in Apr. 2026 was 0.00%.

Eastwood Bio-Medical Canada  (TSXV:EBM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eastwood Bio-Medical Canada ROCE % Related Terms

Eastwood Bio-Medical Canada ROCE % Historical Data

* Premium members only.

The historical data trend for Eastwood Bio-Medical Canada's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eastwood Bio-Medical Canada ROCE % Chart

Eastwood Bio-Medical Canada Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -325.75 0.00 0.00 0.00 0.00

Eastwood Bio-Medical Canada Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:EBM
25GF Score
Eastwood Bio-Medical Canada Inc TSXV:EBM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eastwood Bio-Medical Canada ROCE % Calculation

Eastwood Bio-Medical Canada's annualized ROCE % for the fiscal year that ended in Oct. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Oct. 2025 )  (A: Oct. 2024 )(A: Oct. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Oct. 2025 )  (A: Oct. 2024 )(A: Oct. 2025 )
=-0.292/( ( (0.274 - 1.571) + (0.219 - 1.848) )/ 2 )
=-0.292/( (-1.297+-1.629)/ 2 )
=-0.292/-1.463
=19.96 %

Eastwood Bio-Medical Canada's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=-0.256/( ( (0.251 - 1.901) + (0.265 - 1.982) )/ 2 )
=-0.256/( ( -1.65 + -1.717 )/ 2 )
=-0.256/-1.6835
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Eastwood Bio-Medical Canada (TSXV:EBM) has a ROCE % of 0.00% as of Apr. 2026.
Is Eastwood Bio-Medical Canada's ROCE % too high?
Eastwood Bio-Medical Canada's current ROCE % is 0.00%. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's ROCE % compare to VRTX and REGN?
Eastwood Bio-Medical Canada's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Eastwood Bio-Medical Canada's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current ROCE % is 0.00%. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current ROCE % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?

Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued. The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53. GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.

Key valuation signals for TSXV:EBM:

  • ROCE %: 0.00%
  • GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eastwood Bio-Medical Canada Business Description

Address 4871 Shell Road, Suite 1130, Richmond, BC, CAN, V6X 3Z6
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score

Get the complete analysis for TSXV:EBM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.99
Price
C$0.53
GF Value